Americafirst Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Americafirst Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-9,110	Closed	-$303K	–	246
2017 Q2	$303K	Buy	+9,110	New	+$282K	0.38%	89
2016 Q4	–	Sell	-32,767	Closed	-$1.51M	–	247
2016 Q3	$1.51M	Buy	+32,767	New	+$1.71M	1.25%	39
2015 Q1	–	Sell	-15,924	Closed	-$916M	–	339
2014 Q4	$916M	Sell	15,924 -33,864	-68%	-$1.89M	0.44%	75
2014 Q3	$2.68B	Buy	+49,788	New	+$2.64M	1.32%	12

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Americafirst Capital Management's TEVA Position: Q3 2017 in Review

Americafirst Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 9,110 shares — an estimated $303K sold.

Americafirst Capital Management first reported a position in TEVA in Q3 2014 and held it in 4 quarters. The position peaked at $2.68B in Q3 2014. 536 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Americafirst Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Americafirst Capital Management sold 9,110 Teva Pharmaceuticals shares in Q3 2017, an estimated $303K.
Americafirst Capital Management first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 4 quarters.
Americafirst Capital Management's Teva Pharmaceuticals position peaked at $2.68B in Q3 2014.
536 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Americafirst Capital Management's 13F filing for Q3 2017, filed 16 Nov 2017.